Geographic Atrophy clinical trials at UCSF
1 in progress, 1 open to new patients
-
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
open to eligible people ages 55 years and up
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).
San Francisco, California and other locations